Dihydropyrimidine-thiones and clioquinol synergize to target beta-amyloid cellular pathologies through a metal-dependent mechanism by Tardiff, Daniel F. et al.
Boston University
OpenBU http://open.bu.edu
Chemistry BU Open Access Articles
2017-09-01
Dihydropyrimidine-thiones and
clioquinol synergize to target
beta-amyloid cellular patholog...
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version
Citation (published version): Daniel F Tardiff, Lauren E Brown, Xiaohui Yan, Richard Trilles, Nathan
T Jui, M Inmaculada Barrasa, Kim A Caldwell, Guy A Caldwell, Scott E
Schaus, Susan Lindquist. 2017. "Dihydropyrimidine-Thiones and
Clioquinol Synergize To Target beta-Amyloid Cellular Pathologies
through a Metal-Dependent Mechanism." ACS CHEMICAL
NEUROSCIENCE, Volume 8, Issue 9, pp. 2039 - 2055 (17).
https://doi.org/10.1021/acschemneuro.7b00187
https://hdl.handle.net/2144/40468
Boston University
Dihydropyrimidine-Thiones and Clioquinol Synergize To Target 
β-Amyloid Cellular Pathologies through a Metal-Dependent 
Mechanism
Daniel F. Tardiff*,†,∇, Lauren E. Brown‡, Xiaohui Yan§, Richard Trilles‡, Nathan T. Jui||,○, M. 
Inmaculada Barrasa†, Kim A. Caldwell§, Guy A. Caldwell§, Scott E. Schaus‡, and Susan 
Lindquist†,⊥,#,◆
†Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, United States
‡Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, Boston, 
Massachusetts 02215, United States
§Department of Biological Sciences, The University of Alabama, Tuscaloosa, Alabama 35487, 
United States
||Department of Chemistry, MIT, Cambridge, Massachusetts 02139, United States
⊥Department of Biology, MIT, Cambridge, Massachusetts 02139, United States
#Howard Hughes Medical Institute, Cambridge, Massachusetts 02139, United States
Abstract
The lack of therapies for neurodegenerative diseases arises from our incomplete understanding of 
their underlying cellular toxicities and the limited number of predictive model systems. It is 
critical that we develop approaches to identify novel targets and lead compounds. Here, a 
phenotypic screen of yeast proteinopathy models identified dihydropyrimidine-thiones (DHPM-
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thiones) that selectively rescued the toxicity caused by β-amyloid (Aβ), the peptide implicated in 
Alzheimer’s disease. Rescue of Aβ toxicity by DHPM-thiones occurred through a metal-
dependent mechanism of action. The bioactivity was distinct, however, from that of the 8-
hydroxyquinoline clioquinol (CQ). These structurally dissimilar compounds strongly synergized at 
concentrations otherwise not competent to reduce toxicity. Cotreatment ameliorated Aβ toxicity by 
reducing Aβ levels and restoring functional vesicle trafficking. Notably, these low doses 
significantly reduced deleterious off-target effects caused by CQ on mitochondria at higher 
concentrations. Both single and combinatorial treatments also reduced death of neurons expressing 
Aβ in a nematode, indicating that DHPM-thiones target a conserved protective mechanism. 
Furthermore, this conserved activity suggests that expression of the Aβ peptide causes similar 
cellular pathologies from yeast to neurons. Our identification of a new cytoprotective scaffold that 
requires metal-binding underscores the critical role of metal phenomenology in mediating Aβ 
toxicity. Additionally, our findings demonstrate the valuable potential of synergistic compounds to 
enhance on-target activities, while mitigating deleterious off-target effects. The identification and 
prosecution of synergistic compounds could prove useful for developing AD therapeutics where 
combination therapies may be required to antagonize diverse pathologies.
Graphical Abstract
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INTRODUCTION
Protein misfolding causes a diverse set of neurodegenerative diseases (ND) that exact a 
tremendous personal and socioeconomic burden. Each disease is characterized by the 
stereotypic insult of a disease-specific protein on distinct neuronal subpopulations. The 
dysfunction and death of neurons manifest in diverse clinical pathologies, ranging from 
motor defects to dementia. Our lack of effective disease-modifying therapies for these 
disorders has obvious and significant ramifications as the number of aged individuals 
continues to increase.
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To elucidate the relationship between neurotoxic proteins and cell pathology, we and others 
have exploited the unique advantages of budding yeast. Yeast harbor nearly all the same 
conserved cellular pathways as human neurons, including vesicle trafficking, mitochondrial 
function, lipid biology, and most aspects of protein homeostasis.1–3 Moreover, the genetic 
tractability of yeast and its ease of growth enable unparalleled genetic and chemical screens 
in defined, genetically homogeneous cell populations. Several disease proteins, including α-
synuclein (α-syn, Parkinson’s disease, PD), amyloid-β peptide (Aβ, Alzheimer’s disease, 
AD), and TDP-43 (amyotrophic lateral sclerosis/ALS and frontotemporal lobar 
degeneration/FTLD) elicit specific perturbations to cellular pathways in yeast that lead to 
overt cytotoxicity.4–6
Using the yeast Aβ model, critical links have been established between cellular pathologies 
caused by intracellular Aβ and characteristics specific to the human disease. In humans, Aβ 
is produced throughout life as a cleavage product from the amyloid precursor protein (APP), 
and, in AD patients, it accumulates in the form of extracellular amyloid plaques.7,8 Although 
these plaques are conspicuous disease hallmarks, healthy, nondemented individuals also 
exhibit Aβ plaque burden,9 suggesting that it is actually smaller assemblies of Aβ oligomers 
that poison neuronal function and cause disease. In the yeast model, a signal sequence is 
added to the Aβ expression construct so that the Aβ peptide is cotranslationally imported 
into endoplasmic reticulum (ER). The signal sequence is then cleaved and native Aβ forms 
oligomers within the secretory and endosomal compartment that elicit cellular toxicity. 
Importantly, the yeast model recapitulates the enhanced pathogenicity and oligomer 
formation of the Aβ1–42 peptide (as compared to Aβ1–40) observed in AD.10,11 Related 
yeast models have used a non-native Aβ-GFP fusion protein expressed directly in the 
cytoplasm, where it causes cellular toxicity and aggregates.12
The robust growth inhibition caused by secretory Aβ expression in yeast enabled two 
unbiased phenotypic screens for modulators of Aβ toxicity, one genetic4 and one 
chemical.13 From the genetic screen, we identified several genes that function in 
endocytosis, suggesting that Aβ poisons this process. Indeed, endosomal transport was 
largely abrogated in Aβ-expressing yeast. Even more strikingly, multiple genetic modifiers 
were shown to be yeast homologues of, or to interact with, known human AD risk 
alleles.14–18 One example, PICALM, is one of the most highly validated risk factors for AD, 
aside from APOe4.14,19 A conserved mechanism of toxicity with relevance to neurons was 
further supported by the demonstration that homologues of the yeast genetic modifiers 
reversed Aβ toxicity in both nematode and mammalian neurons. A genetic screen of an Aβ-
GFP model revealed related pathways, where phospholipid metabolism was implicated in 
mediating toxicity.20 Thus, unbiased screens using the yeast Aβ model can identify genes 
that are directly related to the human disease.
A large-scale Aβ chemical screen of the yeast Aβ model was used to identify compounds 
that restored growth with no preconception of potential protective pathways or targets.13 
Once uncovered, the cytoprotective small molecule itself can be used to reveal underlying 
pathological mechanisms and potential drug targets.21 For example, our chemical screen hits 
included several 8-hydroxyquinolines, a class of metal-binding compounds previously 
shown to robustly antagonize Aβ pathology in mouse models of Aβ toxicity. Strikingly, this 
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scaffold has been tested through phase II clinical trials22–25 and, in yeast, operates through a 
metal-dependent stimulation of Aβ degradation in yeast.13 This work indicates that the role 
of metals in Aβ aggregation in AD is recapitulated in the Aβ yeast model.26,27 Specifically, 
it appears that the aggregation-promoting interaction of the Aβ peptide with metals can be 
targeted with metal-binding compounds to promote peptide degradation and cellular rescue. 
Other mechanisms of action targeting misfolded Aβ oligomers can likely be targeted as well. 
Dimebon, for example, enhances autophagy and reduces intracellular levels of GFP-Aβ42 in 
yeast.28 And an Aβ oligomerization yeast model has identified small molecules that target 
toxic Aβ structures directly.29 Thus, multiple different models have revealed a path to 
identifying cytoprotective compounds targeting key aspects of Aβ cellular pathology that 
provide starting points for lead compound discovery.
The ability to robustly identify new chemical matter that suppresses a cellular growth defect 
provides a powerful and unbiased approach to elucidate relevant druggable pathways. Here, 
we expand on our previous screens by reporting screening results from a small, yet diverse, 
chemical library. One series of compounds, dihydropyrimidine-thiones (DHPM-thiones), 
protected cells against Aβ toxicity through a metal-dependent mechanism and strongly 
synergized with a known metal-binding compound in both yeast and nematode models. The 
ability to identify and evaluate synergy between compounds may prove powerful given that 
treating human neurodegenerative disease may require complementary treatment modalities.
RESULTS AND DISCUSSION
Phenotypic Small Molecule Screen Identifies Cytoprotective DHPM-Thiones
To identify new compounds and potential drug targets using the Aβ yeast model, we 
expanded the chemical space that we had previously surveyed by screening a small chemical 
library of novel chemistry (assembled by the Boston University Center for Molecular 
Discovery; BU-CMD). We screened the secretory Aβ model against ~3000 compounds and 
monitored growth using optical density at 24 and 48 h after inducing toxic protein 
expression with galactose and administering screening compounds. Hits were identified by 
calculating Z-scores relative to the plate mean and using a 3σ cutoff.
This screen identified a small number of compounds that partially rescued cells from Aβ 
toxicity (Figure 1A). These initial hits were selective for Aβ toxicity, as yeast models 
expressing α–synuclein, TDP-43, and htt72Q were not rescued by the hits in parallel 
analyses (Figure 1B). This selectivity profile suggests that Aβ elicits cellular pathologies 
distinct from those of the other models, and that the target of this hit series specifically 
ameliorates this pathology.4–6,30
Analysis showed that the chemical structure of the six hit compounds (1–6) comprised a 
dihydropyrimidine-thione scaffold (DHPM-thiones; Figure 1C). These heterocyclic 
compounds had either ethyl or benzyl substituents at N1 (R1 indicated in Figure 1C) and a 
range of substituted phenyl rings at C4. This particular scaffold has been extensively studied 
based on its robust, accessible synthesis via the Bignelli reaction, a three-component, one-
pot reaction that is amenable to library-type synthesis. We took advantage of the flexible 
nature of DHPM-thione synthesis to construct 82 additional analogues (10) (Figure 2 and 
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Supporting Information Table S1, Methods S1) for further evaluation of structure–activity 
relationships (SAR). We incorporated various alkyl and benzylic substituents at R1, 
alterations in phenyl ring substitution at R2, and either methyl esters or methyl ketones at the 
5-position (only the methyl ester is indicated in Figure 1C). The resulting DHPM-library 
was then evaluated for efficacy against Aβ toxicity in yeast.
Dose-response curves of each analogue using the Aβ yeast strain revealed that many 
compounds retained significant efficacy (Figure 3A). All compounds synthesized lacking an 
R1 substituent (derived from thiourea 7{1}) were inactive, indicating a strict requirement for 
substitution at this position. Within R1-substituted analogues, we compared the isobutyl and 
substituted benzyl analogues. Active compounds within each of these groups achieved 
comparable levels of Aβ rescue (Figure 3B, left plot). Substituted benzyl derivatives, 
however, exhibited overall increased potency as compared to isobutyl analogues (P < 
0.0001; Figure 3B, right plot). While aromatic halides contribute to increased 
hydrophobicity (Supporting Information Table S1), it is likely that these structural changes 
enable the compounds to more efficiently engage a target. For example, if these compounds 
bind a hydrophobic pocket, increasing this character with an associated increase in target 
affinity may improve potency. We also evaluated the impact of R3 as a ketone or an ester 
within the context of isobutyl or benzyl R1 substituents. These two modifications did not 
significantly impact efficacy or potency of either subseries of DHPM-thione (Supporting 
Information Figure 1); thus, this position appeared less important for target engagement.
One of the more potent compounds from this series was 10{3,3,1} (Figure 3C), an N-benzyl, 
methyl ketone DHPM-thione with 4-chlorophenyl substitution at R2. To examine whether 
the thiourea function was important to activity, we made the corresponding urea substitution 
(11, Figure 3C). Along with 10{3,3,1} and 11, we also tested monastrol (a characterized 
DHPM-thione that targets kinesin-531) and clioquinol (CQ), an 8-hydroxyquinoline with 
demonstrated efficacy in both yeast and neuronal models of Aβ toxicity.13,22,23 Neither the 
oxygenated analogue 11 nor monastrol rescued Aβ toxicity (Figure 3D). These results 
indicated the requirement for a thiourea and were consistent with our earlier observations 
that R1-unsubstituted DHPM-thiones did not exhibit rescue. In addition to the thiourea and 
R1 substitutions, diverse substituted phenyl R2 substituents were tolerated, as were ketone or 
ester derivatives. Thus, while multiple substitutions were at least partially tolerated, the 
range of effects on potency and efficacy suggest that this series engages a protein target. 
These data are summarized in Figure 3E.
DHPM-Thiones Protect against Aβ Toxicity in a Nematode Model
While the yeast advantages of genetic tractability and ease of growth are clear, they of 
course, lack the cell-to-cell contacts and communication inherent to a functioning nervous 
system.32 We therefore used a nematode model to test if DHPM-thiones could ameliorate 
Aβ toxicity in a fully intact nervous system. In our Caenorhabditis elegans model, Aβ is 
targeted to the secretory pathway in the same manner as in our yeast model.4 Using a 
glutamatergic neuron-specific promoter, we monitored Aβ proteotoxicity in six tail 
glutamatergic neurons in the nematode and scored the number of viable neurons over the 
course of 5 days. Importantly, the progressive neurotoxicity elicited by Aβ in these neurons 
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is attenuated by the same genetic and small molecule modulators that were identified in 
unbiased yeast screens,33 indicating a conserved mechanism of Aβ toxicity from yeast to 
neurons.
Early larval stage worms were treated with compound for 24 h, after which, worms were 
allowed to develop and age in the absence of compound for 4 days (Figure 4A). Toxicity was 
then assessed by counting the remaining GFP-positive glutamatergic neurons. Consistent 
with previous results,13,34 CQ increased the survival of Aβ-expressing glutamatergic 
neurons (Figure 4B, red). Two active DHPM-thiones (10{6,3,1} and 10{3,3,1}) partially 
reduced Aβ toxicity at 15 and 30 μM (Figure 4B, blue), while inactive compounds 10{1,2,1} 
and 11 failed to confer protection (Figure 4B, green). Representative fluorescent microscopy 
images of individual worms treated with solvent DMSO alone or compounds shows the 
position and viability of Aβ-expressing neurons (Figure 4C). The efficacy of the DHPM-
thiones in yeast, as well as neurons, suggests that both the mechanism of Aβ toxicity and the 
mechanism of DHPM-thione rescue are fundamentally conserved across significant 
evolutionary distance.
DHPM-Thiones Impinge on Metal Homeostasis
To begin our investigation into the mechanism of action (MOA) for the cytoprotective 
DHPM-thiones, we assessed changes in gene expression that were specific to the active 
compound 10{3,3,1} as compared to both the oxygenated analogue 11 and CQ. Wild-type 
yeast were treated with CQ, 10{3,3,1}, or 11 at each compound’s effective dose for 6 h, and 
then the cells were harvested for mRNA sequencing analysis.
Wild-type cells treated with each compound yielded distinct gene expression profiles, with 
CQ most dramatically inducing changes in mRNA abundance (Figure 5A, Table S2). As 
anticipated based on the known metal-binding capacity of CQ, gene ontology analysis of 
CQ-treated cultures revealed a clear metal-depletion signature as transcripts involved in 
copper and iron import increased in abundance, while those encoding proteins functioning in 
mitochondria (including electron transport chain, ETC) and metabolism (e.g., TCA cycle) 
dramatically decreased in abundance (Figure 5B). Interestingly, the active analogue 
10{3,3,1} specifically increased metal-related genes compared to the inactive analogue 11 
(Figure 5A and B, Table S2), although the magnitude of change was significantly greater for 
CQ than 10{3,3,1}. Importantly, as compared to 10{3,3,1}, metal-responsive genes 
remained unchanged upon treatment with the urea analogue, 11 (Figure 5C). Evaluation of a 
subset of genes from the RNA-seq data set reveals this more clearly (Figure 5C and D). 
Comparison of the entire group of metal-responsive genes revealed a highly significant 
difference between the active and inactive analogue (Figure 5C, right panel).
Phosphate metabolism genes were also induced by 10{3,3,1} (Figure 5B and D). However, 
the inactive 11 also induced this gene set, albeit to a lesser extent (Figure 5D). This data was 
insufficient to discern whether the metal or phosphate signatures were relevant to Aβ rescue. 
Regardless, it is likely that the signatures most strongly correlating with Aβ rescue were 
relevant to on-target activity. In this case, this suggested an interaction with metal 
homeostasis may be most related to Aβ rescue. After obtaining these results, we further 
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confirmed that 10{6,3,1} and 10{3,3,1} interacted with cellular metal homeostasis: 
compromising cellular metal levels either through genetic or pharmacological means led to 
an enhanced sensitivity of cells to both CQ and DHPM-thiones, while the unrelated Rsp5-
activating compounds (NAB2)21 had no effect (Supporting Information Figure 2).
DHPM-Thiones Rescue Aβ Toxicity in a Metal-Dependent Manner
Both metal and phosphate metabolism genes were altered in response to 10{3,3,1} (Figure 
5C and D). We therefore tested whether modifying these pathways influenced rescue by 
either CQ or 10{3,3,1}. A set of genes encompassing both metal homeostasis and phosphate 
metabolism functions were evaluated for modulatory effects on rescue by CQ and 10{3,3,1} 
(Figure 6A and B). Expression of iron-responsive transcription factors AFT1 and AFT2 
reduced rescue by both CQ and 10{3,3,1}. However, this was due to overall reduced growth 
of the Aβ strain caused by AFT1/AFT2 overexpression (Supporting Information Figure 3). 
Two genes, FRE1 and FRE2, specifically mitigated rescue by 10{3,3,1} as compared to CQ 
(Figure 6A), without having any effects on Aβ growth on their own (Supporting Information 
Figure 3). The products of these two genes are the major cell surface copper and iron 
reductases that reduce Cu(II) and Fe(III) to the bioavailable Cu(I) and Fe(II) forms.35,36 
FRE1/FRE2 overexpression may increase intracellular copper and/or iron levels in a manner 
that antagonized the protective effect of 10{3,3,1} on Aβ toxicity.
In contrast to metal-related genes, overexpression of phosphate metabolism genes had no 
effect on rescue by neither CQ nor 10{3,3,1} (Figure 6B). A trend toward an effect by PHO4 
overexpression on 10{3,3,1} was not statistically significant. We therefore posited that the 
metal homeostasis signature was more relevant in ameliorating Aβ toxicity than the 
phosphate metabolism genes. Full dose–response curves show that the reversal of Aβ rescue 
conferred by FRE1/FRE2 overexpression was distinct between CQ and 10{3,3,1}, indicating 
these two compounds likely work through different mechanisms of action (Figure 6C). To 
reconcile the partial effect of 11 on phosphate metabolism genes, it is possible that there are 
multiple targets of this scaffold. Some targets are shared between the active and inactive 
analogues independent of the urea or thiourea moiety, but only the metal-dependent target 
mediates rescue of Aβ toxicity. Alternatively, the inactive compound may inefficiently 
engage the target, which was sufficient to elicit a partial response that was insufficient to 
elicit the metal response or rescue Aβ toxicity.
To further examine whether the rescue of Aβ toxicity was due to a metal-dependent target, 
we added exogenous copper or iron to determine if they could compete with the compound 
for the target. As shown previously,13 copper prevented rescue by CQ, while iron shifted the 
dose–response and reduced toxicity at higher concentrations (Figure 6D). Consistent with 
the FRE1/FRE2 overexpression result, exogenous copper and iron fully blocked rescue by 
10{6,3,1} (Figure 6D). These results further corroborate the gene expression data and 
overexpression studies, indicating the rescue by DHPM-thiones likely operates through a 
target that binds to copper or iron.
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DHPM-Thiones Directly Bind Copper Ions
Thus far, data indicate that rescue of Aβ by both CQ and DHPM-thiones operate through a 
mechanism that operates through metal homeostasis or a specific metalloprotein. There are 
two possible mechanisms by which DHPM-thiones could elicit these phenotypes. Either 
DHPM-thiones rescue Aβ through a metal-dependent process that can be antagonized by 
genetic or pharmacological alterations in metal bioavailability (Figure 6C and D), or DHPM-
thiones directly bind metal–either freely or as part of metalloprotein–to elicit a protective 
response.
To test whether DHPM-thiones bind metal directly, we first used UV/vis absorbance profiles 
to monitor copper. As expected, the addition of Cu(II) specifically altered the UV/vis spectra 
of CQ (Supporting Information Figure 4). For 10{3,3,1}, there was a modest change to the 
absorbance profile when treated with Cu(II) (Figure 7A); however, 11 exhibited no change 
in the UV/vis absorbance profile (Figure 7B), suggesting the difference in absorbance was 
due to Cu(II) binding. To further substantiate this result, we used nuclear magnetic 
resonance (NMR) with 10{3,3,1} and 11 in combination with Cu(I), as Cu(II) is 
incompatible with NMR. Chemical shifts indicative of metal binding were detected with 
10{3,3,1} in the presence of copper (Figure 7C, top). In contrast, 11 showed no evidence of 
metal binding (Figure 7C, bottom), consistent with the UV/vis result. Together with the 
genetic modulation (Figure 6C) and metal competition (Figure 6D) experiments, these data 
strongly suggest that DHPM-thione rescue of Aβ toxicity occurs through a mechanism and 
target whose activity is impacted by metal binding.
Although not as prevalent as for 8-hydroxyquinoline metal ligands, thioureas can complex 
with metals to target metalloproteins. Examples of bioactive thionyl-containing compounds 
that require metal-binding for their activity include hydroxypyrothione and 
hydroxypyridinethione inhibitors of metalloproteinases,37 as well as diisopropylthiourea-
based antimicrobial agents.38 More recently, a multifunctional pyrimidinylthiourea with both 
inhibitory acetylcholine esterase activity and metal-binding potential were effective in vitro 
and in vivo.39
The data presented here thus provides a direct link between bioactive thiourea-based metal 
ligands and the toxicity caused by the Aβ peptide implicated in AD. This identification of 
another class of metal-dependent cytoprotective compounds underscores the significant 
evidence linking Aβ and metal-dependent phenomenology in AD. Metals bind and promote 
Aβ aggregation, facilitate formation of reactive oxygen species (ROS), accumulate in 
extracellular plaques, and are depleted in the surrounding areas.26,27 Thus, the ability to 
mitigate these effects and potentially redistribute bioavailable metal is a viable therapeutic 
strategy that has been pursued, especially with the 8-hydroxyquinoline, PBT2.19,23
Mechanism of Action: Evaluation of the Effects of CQ and DHPM-Thiones on Aβ Levels 
and Vesicle Trafficking
To evaluate the mechanism of action for DHPM-thiones, we first examined the effects of 
10{6,3,1} on steady-state Aβ peptide levels. Confirming previous observations,13 
immunoblot analysis revealed that CQ reduced Aβ peptide levels by ~80% at its most 
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effective concentration of 0.8 μM (Figure 8A, top panel). This reduction was consistent with 
CQ preventing and/or reversing the metal-dependent oligomer formation and promoting Aβ 
degradation. Compound 10{6,3,1}, in contrast, did not reduce Aβ levels under these 
conditions (Figure 8A, top panel).
We simultaneously assessed the effects of CQ and 10{6,3,1} on restoration of vesicle 
trafficking using Cpy as representative trafficking protein substrate. Cpy is a vacuolar 
protease that is trafficked from the ER to the Golgi, where it is post-translationally modified 
through glycosylation.40 Cpy then traffics through multivesicular bodies to the vacuole and 
is cleaved to yield the active Cpy protease. Defects in trafficking from ER-to-Golgi and from 
the Golgi-to-vacuole can lead to accumulation of immature Cpy. Thus, monitoring Cpy 
trafficking can illuminate the trafficking defects caused by α-syn in yeast.5 Additionally, 
defects in recycling of its receptor from the vacuole back to the Golgi (via the retromer) can 
indirectly influence Cpy trafficking. We therefore performed immunoblot analysis of Cpy in 
both WT and Aβ-expressing yeast to monitor changes in the ratio of immature to fully 
processed Cpy.
After inducing Aβ expression, improperly trafficked Cpy accumulated, indicating Aβ 
inhibits features of secretory or endosomal trafficking (Figure 8A, middle panel; quantitation 
in Figure 8B). Given our previous demonstration that secretion was not inhibited by Aβ 
expression,4 this defect is likely due to dysfunctional endosomal transport consistent with 
the Mup1-GFP, Ste3-GFP, and clathrin defects we previously observed.4,13 The Cpy defect 
was fully reversed by CQ; compound 10{6,3,1} did not significantly reduce the Cpy 
trafficking defect (Figure 8A, middle panel and Figure 8B). It thus does not appear that 
DHPM-thiones confer cytoprotection against Aβ toxicity by reversing trafficking defects.
Mechanism of Action: Evaluation of CQ and DHPM-Thiones Effects on Aβ-Induced ROS 
Generation
The generation of reactive oxygen species (ROS) is a toxic common feature of many 
neurodegenerative disease models. ROS may be generated by dysfunctional mitochondria 
either when transition metals, such as copper and iron, directly catalyze the conversion of 
H2O2 to highly reactive hydroxyl radicals, or when the disease proteins themselves catalyze 
this conversion. Aβ-metal complexes, for example, can directly facilitate generation of 
ROS.41 In yeast, targeting Aβ to the secretory pathway has also been reported to facilitate 
ROS generation and mitochondrial dysfunction.42 We therefore tested whether the yeast Aβ 
model generates ROS, and, if so, was this phenotype reversed by CQ or DHPM-thiones.
Wild-type and Aβ-expressing yeast were shifted to galactose for 7 h and ROS detected using 
CM-H2DCFDA, which fluoresces green when oxidized. After 7 h, the percent of ROS-
positive cells modestly increased (Figure 8C), consistent with previous results.42 We next 
tested whether CQ and/or 10{3,3,1} could prevent this accumulation. Aβ was induced with 
simultaneous compound administration and ROS levels evaluated after 7 h. For comparison 
with Aβ levels and trafficking defects, the same samples were also assessed for by 
immunoblotting against Aβ peptide and Cpy. CQ reduced ROS generation with a dose–
response that was slightly shifted toward lower concentrations as compared to the reduction 
in protein level (Figure 8D). This shift suggests that CQ can reduce ROS before the dramatic 
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reduction of protein levels. Treatment with 10{3,3,1} also reduced ROS generation, albeit 
without reducing Aβ levels (Figure 8E). Interestingly, the doses at which ROS reduction 
occurred were significantly lower than those required for rescue. This may suggest that the 
compound was not stable during the duration of a growth assay (48 h), or, that the compound 
may be modified while exerting its protective activity. In addition, the results with 10{3,3,1} 
indicate that reversal of ROS could be accomplished without reducing Aβ levels or restoring 
vesicle trafficking.
To test whether 10{3,3,1} rescued Aβ toxicity by directly reducing ROS, we examined (1) 
whether antioxidants could rescue Aβ toxicity and (2) if 10{3,3,1} could rescue H2O2 
toxicity. We first evaluated the ability of a robust antioxidant, N-acetylcysteine (NAC), to 
rescue Aβ toxicity. If simple radical scavenging was a productive mode of action, then NAC 
should at least partially reduce Aβ toxicity. Dose–response analysis showed that while CQ 
and 10{3,3,1} rescued toxicity, NAC at concentrations from 0.5 to 10 mM had no effect on 
Aβ toxicity in yeast (Figure 8F). Note that these concentrations of NAC were ~1000-fold 
higher (mM vs μM) than that required for CQ or 10{3,3,1} efficacy. The opposite question 
was then asked: could CQ or 10{3,3,1} reduce ROS toxicity? We tested a concentration of 
H2O2 that reduced the growth of wild-type yeast by ~80% over a 24 h period and examined 
dose–response curves for each compound. While NAC strongly reduced H2O2 toxicity with 
an EC50 of ~1.5 mM, CQ and 10{3,3,1} conferred no protection (Figure 8G).
These data suggest that ROS itself is not the primary source of toxicity in the Aβ yeast 
model and that neither CQ nor 10{3,3,1} rescue Aβ toxicity by simply scavenging radicals 
or reducing metal-catalyzed H2O2 production. However, this result does suggest that the 
dysfunctional process leading to ROS generation–not the ROS itself–is likely contributing to 
toxicity. For example, if Aβ-influenced mitochondrial function is leading to ROS generation, 
then CQ and DHPM-thiones could reduce ROS because of their main function in rectifying 
a dysfunctional process. In such a scenario, NAC would not be expected to confer 
cytoprotection as the underlying process would remain dysfunctional. For CQ, the reduction 
of ROS-generating dysfunction closely follows a reduction in Aβ levels. 10{3,3,1}, in 
contrast, achieved a reduction in ROS without appreciably affecting Aβ or vesicle 
trafficking, thereby indicating these processes can be uncoupled and independently targeted 
pharmacologically.
CQ and 10{6,3,1} Synergize To Rescue Aβ Toxicity in Yeast and Nematode Aβ Models
CQ displayed distinct rescuing activities and phenotypic responses in metal-related 
experiments as compared to the DHPM-thiones 10{6,3,1} and 10{3,3,1}. While both bound 
metals to rescue Aβ toxicity, they appear to have variable effects on cell physiology, such as 
gene expression profile differences and variable responses to FRE1/FRE2 overexpression 
(Figures 5 and 6). These chemicals also have distinct abilities to facilitate Aβ turnover and 
rescue Cpy trafficking defects (Figure 8). These results and previous studies clearly link Aβ 
rescue to metal-dependent Aβ turnover for CQ (Figure 8).13 However, for the DHPM-
thiones, the metal-responsive protective activity is less clear. Because of these distinct 
activities, we posited that they do indeed work through distinct mechanisms of action. These 
differences provide an opportunity to evaluate any synergistic activity. Compounds that work 
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by the same mechanism of action show additive effects, while those working through 
distinct mechanisms can exhibit synergy. We therefore tested how cells expressing Aβ 
responded to the combination of CQ and 10{6,3,1} in both yeast and worm models.
We examined various combinations of CQ and 10{6,3,1} and compared each combination to 
the single agent dose for their ability rescue Aβ toxicity (Figure 9A). An exceptionally 
strong rescue of Aβ toxicity was achieved with a combined dose of 0.2 μM CQ and 10 μM 
10{6,3,1}, bringing growth almost to the level of WT cells (Figure 9B). At this 
concentration of each compound alone, or even at twice the single agent concentration, there 
was no rescue of Aβ toxicity. Taken together with the distinct behaviors observed in various 
other assays, the synergy between 10{6,3,1} and CQ suggest that they work through distinct, 
complementary mechanisms.
Since both CQ and the DHPM-thiones 10{3,3,1} and 10{6,3,1} individually rescued 
nematode neurons from Aβ toxicity (Figure 4), we next tested if the two compounds also 
synergized in a model with a fully integrated nervous system. Larval stage worms were 
treated with doses of CQ or 10{6,3,1} that were at least 4-fold lower than the active CQ and 
10{6,3,1} doses. The low doses of each compound failed to restore neuronal viability, 
consistent with these doses being sub-effective as single agents (Figure 9C). However, 
combined treatment with lower doses (3.75 μM 10{6,3,1} and 0.125/0.25 μM CQ), 
conferred a robust protection of glutamatergic neurons expressing Aβ (Figure 9C and D). 
Thus, the ability of a combination treatment with DHPM-thiones and CQ to synergistically 
protect against Aβ toxicity is conserved from unicellular yeast through the intact nervous 
system of nematodes, indicating that these distinct mechanisms of action for each compound 
operate within each system.
DHPM-Thione/CQ Synergy Mitigates Off-Target Effects
The supra-additive rescue of the combination treatment suggested that 10{6,3,1} and CQ 
function through distinct mechanisms. To determine if these mechanisms converge on 
altering the levels of Aβ and the associated trafficking defects, we examined the effects of 
synergistic doses by immunoblot as done previously (Figure 10A). Indeed, combined 
treatments of synergistic doses revealed a strong reduction of Aβ levels with concomitant 
rescue of Cpy trafficking (Figure 10A). The most effective combination (0.2 μM CQ and 10 
μM 10{6,3,1}) reduced Aβ and rescued Cpy to a level comparable to treatment with 0.8 μM 
CQ alone. Across all compound treatments, both single and combined, there was a very 
strong correlation between the reduction in Aβ levels and the restoration of functional Cpy 
trafficking (Figure 10B, Supporting Information Figure 5). Thus, the ability of DHPM-
thiones to enhance Aβ turnover and restore Cpy trafficking suggests these compounds may 
contribute to this pathway in a manner not robustly detectable in earlier experiments (Figure 
8). Intriguingly, there were combinations of CQ and 10{6,3,1} that restored trafficking of 
Cpy to a similar extent as the maximal effective dose of CQ, yet the combined treatment 
restored growth to a greater extent than CQ alone (Figure 10B). In particular, the combined 
dose of 0.2 μM CQ and 10 μM 10{6,3,1} led to the same effects on both Aβ rescue and Cpy 
trafficking correction as 0.8 μM CQ alone, yet restored growth to nearly wild-type levels, 
unlike CQ alone (Figure 10C).
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One possible explanation for the enhanced rescue of synergistic doses is that there are 
targets modulated by DHPM-thiones that are independent of Aβ and contribute to additional 
growth rescue, e.g., via the reduction of ROS (Figure 8). Another nonmutually exclusive 
possibility is that the dose-lowering effect of 10{6,3,1} was accomplished by 1) enhancing 
degradation of Aβ, 2) reducing ROS, and, in addition, 3) reducing spurious off-target effects 
on metal-homeostasis caused by CQ. This second possibility was supported by the RNA-seq 
data (Figure 5C), where 10{3,3,1} had modest effects on metal-regulated genes as compared 
to the dramatic effects of CQ, especially on mitochondrial proteins.
To examine how combined treatment generally impacted cellular metal availability, we 
examined the expression of a set of genes whose transcript levels were altered by either CQ 
or 10{3,3,1} (Figure 5C and D). Both 10{6,3,1} and 10{3,3,1} exhibited nearly identical 
synergy patterns, so we used 10{3,3,1} to be consistent with the previous RNA-seq 
experiments. Quantitative RT-PCR analysis was performed on RNA isolated from cells 
treated with the optimal dose of CQ alone (0.8 μM), the optimal synergistic doses (0.2 μM 
CQ, 10 μM 10{3,3,1}), and the single agent doses of the 10{3,3,1} compounds. We first 
examined genes that were upregulated in response to CQ, including iron-(FIT3, FIT2, FRE1, 
FRE2), copper-(FRE1, CTR1), and phosphate-regulated genes (PHO89, PHM6). Consistent 
with the RNA-seq data, 0.8 μM CQ led to a strong up-regulation of metal-regulated genes, 
while 10{3,3,1} had a moderate effect (Figure 10D). The combined, synergistic dose of two 
compounds induced upregulation of these genes to levels comparable to 0.8 μM CQ (Figure 
10D), suggesting the combination promoted a broad metal response. In these experiments, 
phosphate-regulated genes were modestly upregulated by CQ, where they were not in the 
RNA-seq experiments. Combined treatment had little added effect on phosphate genes 
beyond that of 10{3,3,1} alone.
Downregulated genes were affected in a very different manner. Several mitochondrial genes 
functioning in the electron transport chain, some of which are Fe–S-containing proteins 
(e.g., SDH1, CYC1, CYT1, COX26), as well as ERG11 (ergosterol biosynthesis) and 
HEM15 (heme biosynthesis) were significantly down-regulated in response to CQ, but not 
affected by 10{3,3,1} (Figure 10D). Notably, the combined dose, which afforded supra-
additive rescue, did not cause a strong reduction in expression of transcripts encoding 
mitochondrial proteins (Figure 10D). Thus, it appeared that the combination of CQ and 
10{3,3,1} was significantly less impactful on mitochondrial function than CQ alone. This 
difference was likely due to a less pronounced effect on Fe–S cluster-containing proteins.
To test the notion that a competing, deleterious effect on mitochondrial function by the 0.8 
μM dose of CQ limited its rescuing capacity, we overexpressed two proteins that promote 
iron–sulfur cluster generation (ATM1 and YFH1) and monitored rescue of Aβ toxicity. 
Indeed, the overexpression of ATM1 and YFH1 increased Aβ rescue by CQ, yet had no 
impact on Aβ rescue by 10{3,3,1} (Figure 10E). This result at least partially explained how 
maximally effective CQ had the same impact on Aβ and Cpy as the combined dose, yet an 
inferior rescue (Figure 10B): the deleterious off-target cost of maximally effective CQ out-
weighed its effects on Aβ levels and restoration of trafficking. Thus, synergy likely was 
achieved by multiple mechanisms: (1) increasing Aβ turnover (Figure 10B), (2) restoring 
vesicle trafficking, (3) providing additional anti-ROS generating activity (Figure 8E), and (4) 
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simultaneously reducing off-target consequences of CQ on mitochondrial function (Figure 
10D). We have summarized these effects in Figure 10F.
The data presented herein underscores the importance of metal phenomenology in mediating 
Aβ toxicity and adds to the established set of compounds with metal-targeting mechanisms. 
Numerous efforts have led to both the identification and development of compounds with the 
capacity to bind metals with multiple mechanisms of action. Such compounds frequently 
reduce both Aβ levels and metal-dependent H2O2 generation and promote redistribution of 
bioavailable metal ions. Here, DHPM-thiones (herein referred to as a collective class of 
protective compounds unless otherwise noted) exerted protective activity in both yeast and 
nematode models through a metal-dependent mechanism of action that robustly synergized 
with CQ to target Aβ-dependent cellular toxicities.
Although the capacity to bind metals was essential for activity, the identity of the proximal 
metalloprotein target remains unknown. While Aβ itself is a likely candidate as a direct 
target, we did not observe robust effects of DHPM-thiones on Aβ levels or Cpy-trafficking 
reversal. It is possible that our assays could not reveal subtle, yet significant, effects on Aβ 
levels or conformation. However, based on estimates that one-third to one-half of all proteins 
bind a metal ion, there are several hundred proteins that could be targeted.43,44 Thus, 
navigating this expansive set of metalloproteins for one specific activity poses a significant 
challenge. Future efforts will attempt to identify the precise target for DHPM-thiones.
Both individual CQ and CQ/DHPM-thione synergy experiments demonstrated that the 
rescue of Aβ toxicity closely tracked with an ability to reverse vesicle trafficking defects 
(Figure 10). In this case, the rescue of trafficking occurred concomitant with a dramatic 
reduction of Aβ peptide. Based on the data herein, it is not possible to distinguish whether 
Aβ reduction led to a reversal of trafficking, or, if rescuing trafficking led to enhanced 
degradation of Aβ. Regardless, the finding of a tight correlation between rescue and 
correcting an underlying trafficking defect supports accumulating evidence for endosomal 
dysfunction as a prominent molecular feature of AD pathogenesis. In our system, we first 
connected endosomal trafficking defects through the identification of PICALM, a protein 
functioning in endocytosis and a well validated risk factor for AD,14,16,19 in our yeast 
genetic screens.4 Elevating PICALM levels both protected yeast cells from intravesicular 
Aβ, while also mitigating the toxicity of exogenously applied Aβ oligomers to rat primary 
cortical neurons.4 Furthermore, additional AD risk factors BIN1 and CD2AP function in 
vesicle trafficking as well.16,18 These genetic links, along with reports of endosomal 
abnormalities caused by intracellular Aβ,45,46 suggest this may be a key pathway to target 
pharmacologically for AD.
The inability to identify stand-alone therapies for AD partially derives from the fact that 
disease onset and progression are multifactorial processes in which numerous cellular 
pathways are perturbed. For this reason, and given the central role of Aβ in the amyloid 
cascade hypothesis, some efforts have focused on reducing Aβ levels directly. Positive 
indications for potential success of this approach have recently come to light with the early 
results of Adjucanimab, a human-derived antibody that reduced Aβ plaques and slowed 
clinical decline in phase II clinical trials.47 This promise comes in the wake of other less 
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successful attempts at Aβ-targeted antibody therapies.48 Metal-targeting compounds may 
have the added benefit of targeting Aβ via metal-dependent destabilization in addition to 
redistributing bioavailable metals from plaques to surrounding neurons.23 PBT2, an 8-
hydroxyquinoline, also has shown some therapeutic promise, though more recent results 
make its future unclear.24,25 Considering the multifactorial nature of disease progression and 
the limitation of any one given approach, it is plausible that combined therapies may 
ultimately prove important for successful treatment of AD.
While we focused on synergy and dose-lowering capacity here, others have taken a different 
approach to this problem by synthesizing multifunctional compounds. Hybrid compounds, 
many of which are based on 8-hydroxyquinolines, have been rationally designed to target 
multiple toxic attributes of neurodegenerative diseases.49 This approach could have 
particular importance in indications such as AD where multiple metal-dependent 
mechanisms could afford neuroprotection. Numerous other hybrid molecules have been 
developed as potential multifunctional anti-Alzheimer’s agents: flavonoids,50 a benzofuran 
hybrid that inhibits cholinesterase activity and Aβ aggregation,51 and memoquin, which 
combines the acetylcholinesterase inhibitor activity of caproctamine with the antioxidant 
activity of 1,4-benzoquinone,52,53 have demonstrated efficacy in numerous model systems. 
Of particular relevance to the current study, a pyrimidinylthiourea inhibited 
acetylcholinesterase, along with exhibiting activity against multiple Aβ-metal-dependent 
phenomena.39 All activities of this scaffold were enhanced by the thiourea moiety inherent 
to the inhibitory ACh esterase pharmacophore.
Combination therapy is not a new concept and may ultimately be critical for attaining 
maximal patient benefit. Symptom management approaches of cholinesterase inhibitors and 
memantine, for example, slow cognitive decline more effectively than single agent 
treatments.54 While these drugs attempt to maintain levels of acetylcholine and regulate 
glutamate, which have different functions in neurotransmission, they do not themselves 
address the underlying pathologies contributing to AD. Combinations of potential disease-
modifying agents, like those described here or new chemical entities identified from 
phenotypic screens, may be effective in treating disease when combined with symptom 
management drugs that target neuronal function. Cell-based systems amenable to phenotypic 
screening, such as budding yeast, thus provide a path forward to both identify and evaluate 
novel mechanisms for single agents and synergistic combinations of small molecules 
protective against neurodegenerative disease proteins.
METHODS
Yeast Strains
All yeast strains were grown using standard methods. Strains were propagated on solid 
plates composed of complete synthetic media (CSM) containing 2% (w/v) glucose and 2% 
(w/v) agar. Most liquid growth was carried out in complete synthetic media (CSM) 
containing 2% (w/v) of glucose, raffinose, or galactose in 30 °C shaking incubators or 
rotating wheels. Strains harboring plasmids were maintained in media lacking uracil (SX-
Ura, where “X” are sugars) was used to maintain the plasmid. All yeast model strains have 
been described previously4,6,30,60 The af t1Δ strain was generated using pAG3255 (pAG32 
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was a gift from John McCusker (Addgene plasmid # 35122) as a template to PCR amplify 
the hygromycin cassette to knock out AFT1. Transformations were carried out using a 
lithium acetate-based transformations protocol.56 For deletions, following overnight 
recovery in CSM-glucose, cells transformed with the AFT1-targeted hygromycin cassette 
were plated on YPD (yeast extract-peptone-dextrose) plates containing hygromycin (300 μg/
mL). Individual transformants were analyzed by diagnostic PCR to verify deletion of AFT1. 
For experiments using overexpression of metal homeostasis-related genes, Flexgene 
plasmids57 were transformed into the indicated strains and plated on SD-Ura plates to select 
for plasmids harboring the URA3 selectable prototrophic marker.
Compound Screening and Treatments
A library of ~3000 compounds from the Boston University Center for Molecular Discovery 
(BU-CMD) was screened in the α-synuclein, Aβ, TDP-43, and 72Q yeast models. For the 
screen and most compound experiments, strains were grown overnight in CSM-glucose. 
Stationary overnight cultures were then diluted 1:20 in CSM-raffinose for roughly 6 h. 
Strains were then diluted to an OD600 of 0.01 in CSM-galactose to induce expression of the 
toxic genes. For the screen, culture was dispensed to 384-well clear plastic plates and 
compounds pinned using a robotic workstation outfitted with a 100 nL pin tool. Plates were 
then grown under humidified conditions at 30 °C and OD600 read using an Envision 
(PerkinElmer) plate reader after 24 or 48 h. z-Scores were then calculated using the formula 
(OD600 exp well – OD600 plate avg)/(OD600 plate stdev). A z-score of 3.0 was used as a 
cutoff to call screen hits.
The same general growth strategy was used for all compound treatment experiments. 
Compound dilutions for dose–response curves were carried out at a 2× concentration in the 
appropriate media (typically CSM-galactose) in 96-well plates. A 2× concentration of cells 
was then added to the entire plate to achieve the final desired compound concentration and 
cell density. Next, a Tecan Freedom EVO liquid handling robot was used to transfer culture 
(30 μL per well) from the 96-well plate to the four quadrants of a 384-well plate. Following 
a 24 to 48 h incubation and OD600 reading on the Envision plate reader, the average of the 
four wells was used as a single data point and averaged across multiple experiments. Data 
was typically normalized to the maximal rescue conferred by clioquinol (CQ). Raw data was 
first corrected for background OD600 contributed by the plate, a fold-change calculated for 
compound-treated versus DMSO-treated wells, and the maximal rescue for CQ set to 100%. 
For wild-type cell experiments, data was normalized to 100% for the DMSO treated 
condition. For dose–response curves, a logistic regression curve was fit to the normalized 
data using Spotfire (TIBCO). For growth curve experiments, a Bioscreen-C instrument 
(Growth Curves USA) was used to both aerate cultures and read OD600 values at 15 min 
intervals.
Additional variations of the above treatment regimen were also carried out as indicated. 
Exogenous metal competition experiments were carried out by diluting copper chloride or 
iron sulfate to an equimolar concentration as the highest concentration in the dilution plate. 
The compound/metal mixture was then serially diluted along with the compound such that 
an equimolar compound-to-metal concentration was maintained across all points of the 
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dose–response curve. For 1,10-phenanthroline experiments, a final uniform concentration of 
10 μM chelator was used at all doses of CQ or DHMP-thione. For N-acetylcysteine (NAC) 
growth experiments, a dilution of NAC to achieve a final concentration in millimolar, not 
micromolar, was carried out as described above. For H2O2 experiments, a concentration was 
used that achieved ~80% reduction in cell growth after 24 h was used (~0.0015% (w/v)). 
Synergy experiments were carried out by combining CQ and DHPM-thione at indicated 
concentrations. Growth was carried out using the Bioscreen-C instrument, which was used 
for both the growth curves and when growing samples for protein analysis.
DHPM-Thione Synthesis
Synthesis and experimental details of all compounds are described in the Supporting 
Information (Methods S1). The full compound list, properties, and activities are described in 
Table S1.
Nematode Experiments
Nematodes were maintained using standard procedures.58 The transgenic strain, UA198 
{baIn34[-Peat-4::Aβ42; Pmyo-2::mCherry]; adIs[Peat-4::gfp]} was generated as described in 
ref 4. For the analysis of CQ or DHPM effect on Aβ-induced glutamatergic 
neurodegeneration, embryo preparation of UA198 worms was performed and then embryos 
were soaked in CQ or DHPM solution for the following 24 h, during which embryos were 
hatched and worms were age-synchronized59 at L1 larvae stage. Larva worms were rinsed 
three times with M9 solution to be withdrawn from drug treatment, and then transferred onto 
OP50 regular food plates to grow for additional 4 days at 20 °C.
For scoring neurodegeneration, worms were mounted on a 2% agarose pad, immobilized 
with 2 mM levamisole and analyzed with a CCD camera (Photometrics CoolSnap HQ) on a 
Nikon E800 microscope at 40× magnification. Neurodegeneration was considered rescued 
when all five posterior glutamatergic neurons were intact and had no visible signs of 
degeneration. For each drug condition, three independent experiments were performed with 
30 worms in each trial. Statistical analyses were performed using one-way ANOVA in 
GraphPad Prism.
Immunoblot Analysis of Aβ and Cpy
Analysis of Aβ levels and Cpy-trafficking was carried out from cells grown in the 
Bioscreen-C instrument. Treatments were carried out as described above where CSM-
raffinose cultures were diluted into CSM-galactose with the indicated compound treatment 
conditions. For protein analysis, cells were diluted to an OD600 of 0.2 and grown for 8 h. 
Three replicate wells (each 300 μL) were then pooled, centrifuged, washed in cold water, 
and then prepared for protein gels. Given the small volumes, cell pellet size (and roughly 
number) was adjusted to account for differences in cell growth. Cell pellets were 
resuspended in 100 μL of 1× SDS loading buffering and boiled for 15 min. Denatured 
samples were then vortexed for ~30 s and tubes centrifuged for 1 min at 1,000xg to pellet 
cell debris. Samples were resolved by SDS-PAGE (4–12% gradient gels, Invitrogen) in 1X 
MES buffer at 150 V until the dye reached the bottom of the gel. Proteins were then 
transferred to PVDF using an iBlot apparatus (Invitrogen) with a 5 min, 30 s transfer time 
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(reduced time due to small size of Aβ peptide). Prior to transfer, the top one-third of the gel 
was excised and stained for total protein using SimplyBlue SafeStain (Life Technologies). 
After transfer to PVDF, blots were blocked with 5% milk phosphate-buffered saline with 
0.1% (v/v) tween (PBST). Primary antibodies recognizing Aβ (6E10, Covance) and Cpy 
(10A5B5, ThermoFisher) were then incubated overnight with the blots in PBST/5% milk at 
4 °C at a 1:2,000 and 1:5000 dilution, respectively. Blots were washed for 30 min, and 
secondary antibodies added (IRDye800 Licor) for 2 h at room temperature. Blots were 
washed and scanned using a Licor Odyssey instrument to enable quantification. For Aβ 
levels, signal was normalized to the total protein from the stained one-third portion of the gel 
(scanned with Licor Odyssey at 600 nm). For Cpy, the larger molecular weight (ER/Golgi 
localized) band was normalized to the lower molecular weight (mature) Cpy band and 
expressed as a ratio. For both Aβ and Cpy, values were then normalized to the DMSO-
treated condition to monitor effects of compound treatment. At least three independent 
biological replicates were carried out for each experiment.
ROS Experiments
ROS detection was carried out as described previously.60 Briefly, Aβ yeast cultures were 
induced with galactose in the presence or absence of compounds and grown for 7 h in the 
Bioscreen-C instrument. Samples were then taken for ROS detection using a Guava 
easyCyte flow cytometer to measure the oxidation of 5-(and-6)-chloromethyl-2′7′-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA).
Copper-Binding Analysis
UV/vis experiments were carried out by scanning samples from 200 to 600 nM wavelength. 
Compounds (40 mM DMSO stocks) were diluted to 50 μM with or without 50 μM 
copper(II) sulfate in solution containing 1× PBS (pH 7.4) and 50% methanol and incubated 
at room temperature for 15 min prior to UV/vis scanning. Three independent compound 
dilutions and scans were obtained and averaged.
For NMR Cu-binding experiments, A mixture of CuCl (1.0 mg, 0.01 mmol, 1.0 equiv) and 
10{3,3,1} (3.7 mg, 0.01 mmol, 1.0 equiv) in CD3CN was sonicated for 5 min and analyzed 
by 1H NMR. An overlaid comparison of the resulting spectrum to that of 10{3,3,1} alone is 
shown in the figure (Figure 7C, top). In analogy to the above experiment, a mixture of CuCl 
(1.0 mg, 0.01 mmol, 1.0 equiv) and 11 (3.5 mg, 0.01 mmol, 1.0 equiv) in CD3CN was 
sonicated for 5 min and analyzed by 1H NMR. An overlaid comparison of the resulting 
spectrum to that of 11 alone is shown in the figure (Figure 7C, bottom).
Compound Treatment for RNA-seq Experiments
Wild-type yeast (5 mL cultures) grown to log-phase in CSM-galactose were treated with 0.8 
μM CQ, 20 μM 10{3,3,1}, 11, or a DMSO solvent control for 6 h at 30 °C. Cells were 
centrifuged, washed once with ice-cold water, and cell pellets flash frozen in liquid nitrogen 
prior to storage at −80 °C. Cell treatments were carried out in duplicate on separate days. 
RNA was extracted from yeast pellets using a hot acid phenol protocol.61 RNA-seq libraries 
from yeast total RNA (1 μg) were prepared for sequencing with the PrepX RNA-Seq Kit 
from IntegenX according to the standard protocol and sequenced on a HiSeq 2500. Between 
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16 and 26 million 40nt long reads were obtained per sample. Reads were trimmed with 
FASTQ Quality Trimmer (http://hannonlab.cshl.edu/fastx_toolkit/index.html) with 
parameters “-v -t 20 -l 25”. Trimmed reads were mapped using TopHat262 using the 
following parameters: “--no-coverage-search --library-type = fr-secondstrand--solexa1.3-
quals --segment-length 20 -I 2000 --no-novel-juncs” and a gtf file from ENSEMBL release 
65 (Saccharomyces_cerevisiae. EF4.65.gtf). Reads were assigned to genes using htseq-
count63 with parameters “--mode = intersection-strict --stranded = yes”. Read normalization 
and differential analysis was done with DEseq64 Data is found in Supporting Information 
Table S2.
RT-PCR of Compound Treatments
RNA expression was analyzed from wild-type yeast treated with CQ, 10{3,3,1}, or 
combined treatments. CSM-raffinose cultures were transferred to CSM-galactose to an 
OD600 of 0.1 and compounds added. Treated cultures were grown for 6 h at 30 °C. Cells 
were then centrifuged, washedd with cold water, flash frozen in liquid nitrogen, and stored at 
−80 °C. RNA was then isolated using the hot acid phenol method.61 cDNA was generated 
from 500 ng of total yeast RNA using reverse transcriptase (Invitrogen, Superscript III) 
primed with oligo dT (Thermofisher). Gene-specific primers were designed with “Primer3” 
to amplify an approximate 100–150 base pair PCR product localized within the 300 bp 
region of the 3′ end of each gene of interest. Reverse transcribed cDNA was diluted 1:100 
in TE and used as a template in triplicate real-time PCR reactions (Applied Biosystems 
7900HT real time PCR machine). Data was normalized relative to the housekeeping gene, 
ACT1. Four independent experiments were performed and averaged.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Dihydropyrimidine-thiones protect yeast cells against Aβ toxicity. (A) Z-Scores of a small 
molecule screen of the BU-CMD compound collection against our yeast Aβ toxicity model. 
The screen was performed in duplicate (replicates A and B) with the six DHPM-thione hits 
indicated by red circles and numbers. Hits (1) and (4) have overlapping Z-scores. (B) 
Compound plates were also screened against other yeast toxicity models, including α-syn, 
TDP-43, and polyglutamine (72Q). Z-Scores under 3.0 for six DHPM-thione hits indicate 
that the series was selective for the Aβ model. (C) General structure of DHPM-thione hits 
with table indicating R1 and R2 group substituents.
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Figure 2. 
DHPM-thione library generation. A schematic of the general three-component, one-pot 
Biginelli reaction is shown. The 82 compound member library was generated using this 
reaction and combinations of the three components, including (7) thioureas (R1), (8) 
aldehydes (R2), and (9) ketones (R3).
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Figure 3. 
Structure–activity relationships (SAR) of DHPM-thione series. (A) Heat map representation 
of the dose–response curves for 82 DHPM-thiones. Compounds are sorted from highest 
efficacy to lowest efficacy. Red indicates rescue (OD600 values), white indicates no rescue. 
Doses of compounds increased from left to right and range from 2 to 40 μM. The inactive 
cluster of R1-unsubstituted DHPM-thiones is indicated at the bottom of the heat map. (B) 
General structures of isobutyl and substituted/unsubstituted benzyl DHPM-thione analogues 
indicated in yellow and green, respectively, in the following plots. The left plot is efficacy 
and right plot is potency of all analogues falling within that substitution pattern. The y-axis 
for efficacy is fraction of maximal rescue by the series and the y-axis for potency is EC50 
(μM). The indicated P-values were calculated according using a Student’s t test. (C) 
Structures of the thiourea analogue, 10{3,3,1}, and the urea variant, 11. (D) Dose–response 
curves of 10{3,3,1}, 11, CQ, and monastrol. X-axis is concentration (μM) on a log2 scale, 
and y-axis is % of the maximal CQ response. (E) Summary of SAR for R1, R2, R3, and S/O 
urea. While significant tolerability existed within the R1 and R2 groups, a benzylic 
substitution at the R1 group was preferred. The thiourea was required, as was at least an 
alkyl group at R1. Both ketone and ester groups were well-tolerated at R3.
Tardiff et al. Page 27
ACS Chem Neurosci. Author manuscript; available in PMC 2018 September 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
DHPM-thiones rescue nematode model of Aβ toxicity. (A) Schematic of the compound 
treatment regimen for nematode Aβ model. (B) Percent of worms with wild-type number of 
glutamatergic neurons labeled with eat-4::GFP. Three independent experiments were 
performed for each compound (concentration tested in μM) where 30 worms were scored in 
each trial (for a total of 90 worms). P-Values comparing DMSO to each compound were 
calculated using a one-way ANOVA and Tukey’s test. (C) Representative fluorescent images 
of GFP-labeled tail-region glutamatergic neurons in the Aβ nematode model for GFP only 
(i), Aβ plus DMSO (ii), Aβ plus CQ (iii), and Aβ plus compound 10{6,3,1} (iv). Large 
arrowheads indicate neurons. Small arrows with a line indicate a missing neuron.
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Figure 5. 
DHPM-thiones bind copper and alter cellular metal ion homeostasis. (A) Heat map of gene 
expression changes in wild-type yeast cells treated with CQ, 10{3,3,1}, or 11. Cells were 
treated with compound and RNA levels analyzed by RNA-Seq relative to DMSO vehicle 
control. Thresholds were set at a fold change of 2 and a P-value of 10−5 for at least one of 
the treatments. Scale indicates log2 fold change. (B) Gene ontology enrichment for each 
compound treatment. P-Values are indicated on the x-axis. Changes are color-coded 
according to the indicated treatment and direction of effect. (C) Expression data for select 
metal homeostasis genes were extracted from the larger data set and analyzed as a group. 
Scale is as in (A). One-way ANOVA with Tukey’s statistical tests revealed highly significant 
P-values between groups where gene expression changed in response to compound 
treatment (*P < 0.05; ***P < 0.0001). CTR1 was removed from the statistical analysis for 
CQ because it was not significantly altered. (D) Expression data for select phosphate 
metabolism genes were extracted from the larger data set and analyzed as a group. Scale is 
as in (A). One-way ANOVA and Tukey’s statistical tests revealed highly significant p-values 
between groups (*P < 0.05; ***P < 0.001; ****P < 0.0001).
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Figure 6. 
Phenotypic confirmation of a metal-dependent activity for DHPM-thiones and CQ. (A, B) 
Rescue of Aβ by CQ or 10{3,3,1} was examined in the presence of overexpression plasmids 
functioning in (A) metal homeostasis or (B) phosphate metabolism. Maximal rescue is 
reported relative to the response of the maximal rescue of the vector-only control. Three 
independent experiments were performed. (C) Dose–response curves for CQ and 10{3,3,1} 
in Aβ strains harboring empty vector or FRE1/FRE2 overexpression plasmids. X-Axis is 
concentration (μM). Y-Axis is the response of compound as a percent of the maximal rescue 
afforded by CQ. (D) Rescue of Aβ toxicity by both CQ and 10{6,3,1} was reversed by 
exogenous copper (blue) and iron (orange). X-Axis is log2 concentration (μM). Y-Axis is the 
response of compound as a percent of the maximal rescue afforded by CQ.
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Figure 7. 
DHPM-thiones bind copper directly. (A, B) UV/vis absorbance scan of (A) 10{3,3,1} and 
(B) 11 in the presence or absence of equimolar copper(II). Y-Axis is absorbance, and x-axis 
is wavelength (nM). Scans were performed independently three times. (C) NMR spectra of 
10{3,3,1} and 11 in the presence or absence of Cu(I). X-Axis is proton chemical shift 
(ppm).
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Figure 8. 
Effects of compounds on Aβ levels, vesicle trafficking, and ROS generation. (A) Western 
blot analysis of Aβ-expressing yeast treated with increasing doses of CQ or 10{6,3,1}. Top 
panel shows Aβ peptide (higher molecular band is the signal sequence-Aβ fusion prior to 
cleavage). The middle panel is Cpy, where the larger immature Cpy band reflects a block in 
trafficking to the vacuole. Bottom panel is a Coomassie stain of the top portion of the same 
gel used for blotting Aβ and Cpy to show equal protein load. (B) Quantitation of three 
independent experiments of (A). Data was normalized to total protein (quantified by total 
protein) and set to 1.0 for wild-type (Cpy) or Aβ/untreated (Aβ levels). P-Values according 
to a one-way ANOVA and Tukey’s test where P-values are **<0.01 and ***<0.001; 
****<0.0001. (C) Detection of increased reactive oxygen species (ROS) in Aβ-expressing 
yeast compared to wild-type. Aβ was induced for 7 h and ROS detected by flow cytometry 
using a ROS-sensing dye (CM-H2DCFDA). Data are expressed as percent of cells that were 
ROS-positive after 7 h of Aβ expression. (D, E) Dose–response of CQ (D) and 10{6,3,1} (E) 
for both Aβ protein levels (blue) and ROS levels (green). Y-Axis is fraction of Aβ or ROS in 
the untreated condition. X-Axes are concentration (μM). (F) Dose–response curves for 
rescue of Aβ toxicity by CQ, 10{3,3,1}, or the antioxidant N-acetylcysteine (NAC). The y-
axis is percent of maximal rescue by CQ. X-Axis is as in (D). Data indicate that a canonical 
antioxidant could not rescue Aβ toxicity. (G) Dose–response curves for growth of wild-type 
yeast treated with an ~80% lethal concentration of H2O2 in the presence of CQ (red), 
10{3,3,1} (blue), or NAC (green). The y-axis is percent of growth of untreated wild-type 
yeast. X-Axis is as in (D).
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Figure 9. 
CQ and DHPM-thione synergize to rescue Aβ toxicity in both yeast and nematode. (A) 
Quantitation of maximal growth as a percent of wild-type growth over a 48-h time course for 
single or combined doses (as indicated on y-axis) of CQ and 10{6,3,1}. (B) Growth curves 
of wild-type or Aβ-expressing yeast treated with subprotective doses of CQ (0.2 μM) and 
10{6,3,1} (10 μM), as well as their synergistic rescue of combined doses. (C) Synergy of 
CQ and 10{6,3,1} in the nematode model of Aβ toxicity. The y-axis is percent of worms 
with a wild-type number of tail glutamatergic neurons. Black is DMSO solvent control, red 
is CQ, and blue is 10{6,3,1} at subeffective doses. Green is the combination. For each 
treatment condition, three independent experiments were performed with 30 worms scored 
in each trial (a total of 90 worms examined for each condition tested in μM). One-way 
ANOVA with Tukey’s test was used to compare the neurodegeneration among various 
treatment groups. *P < 0.05; **P < 0.01; ***P < 0.001. (D) Representative fluorescent 
images of nematodes expressing Aβ and treated with DMSO alone (i) or the combination of 
CQ/10{6,3,1} (ii). Large arrowheads indicate posterior glutamatergic neurons. Small arrows 
with line indicate a missing neuron.
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Figure 10. 
CQ and DHPM-thiones synergize to reduce Aβ levels, reverse Cpy trafficking deficits, and 
mitigate deleterious off-target effects of CQ. (A) Western blot analysis of Aβ-expressing 
yeast treated with CQ, 10{6,3,1}, or the indicated combinations. (B) Comparison of rescue 
(y-axis) and rescue of Cpy restoration ratio. Compounds are color coded as follows: blue, 
subeffective; red, too high/toxic; orange, synergistic rescue; yellow; subeffective dose. (C) 
Comparison of Cpy trafficking, Aβ levels, and growth for the most synergistic dose of CQ/
10{3,3,1} (0.2 μM CQ and 10 μM 10{3,3,1}) and CQ alone. P-Values were generated with 
one-way ANOVA with Tukey’s test and are indicated on the graph. (D) Heat map of RT-
PCR quantitation of transcripts after treatment with single or combined synergistic doses of 
CQ and 10{3,3,1}. Genes were selected based on changes demonstrated by RNA-seq 
experiments (Figure 5). Scale indicates log2 fold change of transcripts. (E) Quantitation of 
the maximal rescue for Aβ strains with or without overexpression of mitochondrial iron–
sulfur cluster regulating proteins, ATM1 and YFH1. Y-Axis is rescue relative to the maximal 
effect for that compound. One-way ANOVA Tukey’s statistical tests revealed highly 
significant p-values between groups (**P < 0.01; ***P < 0.001). (F) Model of synergy 
between CQ and DHPM-thiones. Red text indicates deleterious effects. Green indicates 
protective effects. The size of the text in the right box reflects their increased/decreased 
activities under synergistic combinations.
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